I

Indiana Hemophilia and Thrombosis Center | Indianapolis, IN

Research site

(Unclaimed)

Location

8326 Naab Road, Indianapolis, Indiana, United States of America

Site insights

Top conditions

Top treatments

Edoxaban

Efanesoctocog Alfa

Voxelotor

DDAVP

Pyruvate

AG-348

SerpinPC

Metformin

Emicizumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 39 total trials

A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B (BENEGENE-2)

This study will evaluate the efficacy and safety of PF-06838435 (a gene therapy drug) in adult male participants with moderately severe to severe hem...

Active, not recruiting

Hemophilia B

Biological: PF-06838435/ fidanacogene elaparvovec

A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B (BEYOND-9)

Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately s...

Enrolling

Hemophilia B

Drug: LNP1265

Drug: REGV131

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy (SYNOVIIIUS)

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week...

Enrolling

Factor VIII Deficiency

Drug: Efanesoctocog alfa

Emicizumab in Patients With Acquired Hemophilia A (AHAEmi)

This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a schedul...

Active, not recruiting

Acquired Hemophilia A

Drug: emicizumab